Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Express Scripts
Dow
McKesson
Johnson and Johnson
Moodys
Boehringer Ingelheim

Last Updated: October 16, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR XELJANZ

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Xeljanz

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01932372 Tofacitinib (Xeljanz) Special Investigation for Rheumatoid Arthritis Active, not recruiting Pfizer N/A 2013-07-01 The objective of this Surveillance is to verify the following subject matters concerning Tofacitinib (Xeljanz) under general practice. 1) Occurrence of adverse reactions, factors that may potentially affect safety and efficacy 2) Long-term safety (particularly, malignant tumors and serious infections) and efficacy Occurrences of malignant tumors and serious infections will be compared with a control group.
NCT02157012 Evaluation of the Condition of Rheumatoid Arthritis After Treatment Recruiting Showa Inan General Hospital Phase 4 2014-05-01 To examine the safety and effectiveness after Xeljanz treatment in rheumatoid arthritis patients
NCT02157012 Evaluation of the Condition of Rheumatoid Arthritis After Treatment Recruiting Shinshu University Phase 4 2014-05-01 To examine the safety and effectiveness after Xeljanz treatment in rheumatoid arthritis patients
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Xeljanz

Condition Name

Condition Name for Xeljanz
Intervention Trials
Rheumatoid Arthritis 5
Alopecia Areata 2
Sacroilitis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Xeljanz
Intervention Trials
Arthritis 6
Arthritis, Rheumatoid 5
Alopecia Areata 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Xeljanz

Trials by Country

Trials by Country for Xeljanz
Location Trials
United States 6
Japan 1
Korea, Republic of 1
Thailand 1
Canada 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Xeljanz
Location Trials
Pennsylvania 2
Oregon 1
Texas 1
Florida 1
New York 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Xeljanz

Clinical Trial Phase

Clinical Trial Phase for Xeljanz
Clinical Trial Phase Trials
Phase 4 4
Phase 3 1
Phase 2 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Xeljanz
Clinical Trial Phase Trials
Not yet recruiting 6
Recruiting 3
Active, not recruiting 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Xeljanz

Sponsor Name

Sponsor Name for Xeljanz
Sponsor Trials
Pfizer 5
Julian M. Mackay-Wiggan 1
Lawson Health Research Institute 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Xeljanz
Sponsor Trials
Other 10
Industry 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Boehringer Ingelheim
Harvard Business School
Baxter
Dow
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.